Shares of Egalet Corp. (NASDAQ:EGLT) saw an uptick in trading volume on Friday . 455,453 shares traded hands during trading, an increase of 120% from the previous session’s volume of 206,995 shares.The stock last traded at $8.47 and had previously closed at $8.40.

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald set a $21.00 price objective on Egalet Corp. and gave the stock a “buy” rating in a research note on Saturday, August 6th. Zacks Investment Research lowered Egalet Corp. from a “hold” rating to a “sell” rating in a research note on Thursday, May 12th.

The company’s market capitalization is $198.80 million. The firm has a 50 day moving average of $6.44 and a 200-day moving average of $6.59.

Egalet Corp. (NASDAQ:EGLT) last posted its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.15. The firm had revenue of $3.45 million for the quarter, compared to the consensus estimate of $3.83 million. The company’s revenue was up 259.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.03) EPS. On average, equities research analysts anticipate that Egalet Corp. will post ($3.47) earnings per share for the current year.

In other news, CFO Stan Musial sold 13,480 shares of Egalet Corp. stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $5.06, for a total value of $68,208.80. Following the completion of the transaction, the chief financial officer now owns 84,940 shares in the company, valued at $429,796.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert S. Radie sold 5,000 shares of Egalet Corp. stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $5.07, for a total transaction of $25,350.00. Following the completion of the transaction, the chief executive officer now owns 259,900 shares of the company’s stock, valued at approximately $1,317,693. The disclosure for this sale can be found here.

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.